Clinical Trial Update: Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease [Phase 1]

View source ↗

Summary

Phase 1 trial in sickle cell disease evaluates escalating doses of Plerixafor to mobilize CD34+ hematopoietic progenitor cells and assesses globin gene transfer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Plerixafor (Plerixafor)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sickle Cell Disease | Phase 1 | Status: COMPLETED